Category - Markets

H.C. Wainwright downgraded Proteon Therapeutics (NASDAQ:PRTO) to “neutral” from “buy” and slashed its price target to $3 from $18, citing a lack of major catalysts that will likely render the shares range-bound. The...

Echelon Wealth Partners initiated coverage of Profound Medical (OTCQX:PRFMF; TSXV:PRN) with a “buy” rating and one-year price target of $4. The stock closed at 78 cents on March 14. Profound has developed MRI-guided...

Aurinia Pharmaceuticals (NASDAQ:AUPH; TSX:AUP) has priced a public offering of 22.3 million common shares at a price of $6.75 each for gross proceeds of about $150.5 million. The offering is expected to close on March...

Shares of Profound Medical (TSX-V:PRN) will be eligible for trading on the OTCQX Best Market under the symbol, PRFMF, effective at the open on March 13. “The U.S. is a key target market for the TULSA-PRO system...

Ladenburg Thalmann launched coverage of Leap Therapeutics (NASDAQ: LPTX) with a “buy” rating and $18 price target. The stock closed at $7.85 on March 6. Leap is a clinical stage immuno-oncology (IO)-focused company with...

Roth Capital Partners has reestablished estimates, a ‘buy” rating, and $17 price target for Aduro Biotech (NASDAQ:ADRO) based on a sum-of-parts, probability-adjusted net present value analysis. The stock closed at $11...

H.C. Wainwright initiated coverage of OSE Immunotherapeutics (ISIN: FR0012127173; Mnémo: OSE) with a “buy” rating and a 12-month price target of €12.00. The stock closed at €6.25 on March 6. OSE Immunotherapeutics is a...

Roth Capital Partners initiated coverage on AxoGen (NASDAQ:AXGN) with a “buy” rating and target price of $14.50. The stock closed at $10 on March 3. “Driven by increased market awareness, surgeon education, clinical...

BTIG downgraded AtriCure (NASDAQ:ATRC) to “neutral,” citing a recent share price rally coupled with an unchanged outlook after the company’s Q4 report. The stock closed at $18.96 on March 3. AtriCure is a medical device...

Stifel raised its price target for Esperion Therapeutics (NASDAQ:ESPR) to $45 from $30. The stock closed at $29.33 on March 2. “We believe Amgen’s recent announcement that Repatha’s FOURIER trial resulted in a...